Oppenheimer Issues Positive Forecast for Savara (NASDAQ:SVRA) Stock Price

Key Points

• Oppenheimer has raised its price target for Savara (NASDAQ:SVRA) from $5.00 to $6.00, suggesting a potential upside of 96.40% from its previous closing price.
• Five investment analysts have given Savara a buy rating, with a consensus target price estimated at $6.17, while some analysts have lowered their price targets following recent reports.
• Insider trading activity shows Director Richard J. Hawkins purchased 48,225 shares of Savara, increasing his stake by 71.72% and raising transparency regarding insider confidence in the company.

Savara (NASDAQ:SVRA - Get Free Report) had its price objective boosted by equities researchers at Oppenheimer from $5.00 to $6.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Oppenheimer's price target would suggest a potential upside of 94.17% from the company's previous close.

Several other brokerages also recently weighed in on SVRA. Guggenheim restated a "buy" rating and issued a $8.00 target price (down from $9.00) on shares of Savara in a research note on Wednesday, May 28th. Evercore ISI decreased their target price on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research note on Wednesday, May 28th. Wells Fargo & Company decreased their target price on shares of Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Wednesday, May 28th. Finally, HC Wainwright upgraded shares of Savara from a "neutral" rating to a "buy" rating and upped their target price for the company from $2.00 to $5.00 in a research note on Friday, August 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $6.17.

Savara Trading Up 1.3%

SVRA traded up $0.04 during trading on Friday, hitting $3.09. 2,135,312 shares of the company's stock were exchanged, compared to its average volume of 1,233,220. The company has a current ratio of 11.08, a quick ratio of 11.08 and a debt-to-equity ratio of 0.25. Savara has a 1 year low of $1.89 and a 1 year high of $4.70. The stock has a 50 day moving average price of $2.44 and a 200 day moving average price of $2.67. The firm has a market cap of $534.08 million, a P/E ratio of -6.18 and a beta of 0.40.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, analysts expect that Savara will post -0.45 EPS for the current fiscal year.

Insider Activity

In other news, Director Richard J. Hawkins acquired 48,225 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were acquired at an average price of $2.04 per share, with a total value of $98,379.00. Following the acquisition, the director directly owned 115,466 shares in the company, valued at approximately $235,550.64. The trade was a 71.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.13% of the company's stock.

Institutional Trading of Savara

A number of large investors have recently modified their holdings of SVRA. Prudential Financial Inc. acquired a new stake in shares of Savara in the 2nd quarter worth about $30,000. BNP Paribas Financial Markets increased its holdings in shares of Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock worth $31,000 after acquiring an additional 4,626 shares during the period. May Hill Capital LLC acquired a new stake in shares of Savara in the 2nd quarter worth about $32,000. Brevan Howard Capital Management LP acquired a new stake in shares of Savara in the 2nd quarter worth about $33,000. Finally, XTX Topco Ltd acquired a new stake in shares of Savara in the 4th quarter worth about $34,000. Institutional investors and hedge funds own 87.93% of the company's stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.